Evogene Ltd.
EVGN
$0.76
-$0.02-2.05%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -1.12% | -19.40% | 331.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -1.12% | -19.40% | 331.52% |
| Cost of Revenue | -- | -- | 40.66% | 25.81% | 104.19% |
| Gross Profit | -- | -- | -19.02% | -37.84% | 690.66% |
| SG&A Expenses | -- | -- | -7.26% | -6.21% | -0.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -25.76% | -4.65% | -14.45% |
| Operating Income | -- | -- | 31.00% | 0.93% | 28.85% |
| Income Before Tax | -- | -- | 43.02% | -3.20% | 34.18% |
| Income Tax Expenses | -- | -- | 124.24% | -118.75% | -58.97% |
| Earnings from Continuing Operations | -- | -- | 42.91% | -3.12% | 34.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -24.39% | -13.37% | -30.17% |
| Net Income | -- | -- | 30.96% | -15.96% | 34.62% |
| EBIT | -- | -- | 31.00% | 0.93% | 28.85% |
| EBITDA | -- | -- | 25.90% | -3.87% | 31.63% |
| EPS Basic | -- | -- | 46.26% | 6.24% | 37.05% |
| Normalized Basic EPS | -- | -- | -- | 57.92% | 45.84% |
| EPS Diluted | -- | -- | 46.26% | 6.24% | 37.05% |
| Normalized Diluted EPS | -- | -- | -- | 57.92% | 45.84% |
| Average Basic Shares Outstanding | -- | -- | 18.67% | 21.39% | 5.17% |
| Average Diluted Shares Outstanding | -- | -- | 18.67% | 21.39% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |